References
Organization WH. WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/. Published 2021. Accessed 20/01/2021, 2021.
2. Gustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-19. Am J Pathol. 2021;191(1):4-17. doi: 10.1016/j.ajpath.2020.08.009.
3. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
4. Becker RC. COVID-19-associated vasculitis and vasculopathy. J Thromb Thrombolysis. 2020;50(3):499-511. doi: 10.1007/s11239-020-02230-4.
5. Wassmann S, Faul A, Hennen B, Scheller B, Böhm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ res. 2003;93(9):e98-103. DOI: 10.1161/01.RES.0000099503.13312.7B.
6. Fang CH, Li JJ, Hui RT. Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome. Med hypotheses. 2005;64(1):192-196. doi: 10.1016/j.mehy.2004.06.018.
7. Novack V, Eisinger M, Frenkel A, et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial.Intensive care med. 2009;35(7):1255-1260. doi: 10.1007/s00134-009-1429-0.
8. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res. 2005;6(1):82. doi: 10.1186/1465-9921-6-82.
9. Radenkovic D, Chawla S, Pirro M, Sahebkar A, Banach MJJocm. Cholesterol in relation to COVID-19: should we care about it?. J Clin Med . 2020;9(6):1909. doi: 10.3390/jcm9061909.
10. Minz MM, Bansal M, Kasliwal RR. Statins and SARS-CoV-2 disease: Current concepts and possible benefits. Diabetes Metab Syndr.2020;14(6): 2063–2067. doi: 10.1016/j.dsx.2020.10.021
11. Fajgenbaum DC, Rader DJ. Teaching Old Drugs New Tricks: Statins for COVID-19?. Cell Metab. 2020;32(2):145-147. doi:10.1016/j.cmet.2020.07.006.
12. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. The Lancet. 2020;395(10229):1014-1015. doi: 10.1016/S0140-6736(20)30633-4.
13. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823-833. doi: 10.1016/S2213-8587(20)30271-0.
14. Bae S, Kim SR, Kim M-N, Shim WJ, Park S-MJH. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2020; heartjnl-2020-317901. doi: 10.1136/heartjnl-2020-317901.
15. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648.
16. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet.2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3.
17. Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res . 2020;126(12):1671-1681.
18. Vasanthakumar N. Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients. Bioessays. 2020;42(11):2000094. doi: 10.1002/bies.202000094.
19. Zhang X-J, Qin J-J, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(2):176-187. e174. doi: 10.1016/j.cmet.2020.06.015.
20. Rossi R, Talarico M, Coppi F, Boriani GJI, Medicine E. Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action. Intern Emerg Med. 2020;15(8):1573-1576. doi: 10.1007/s11739-020-02504-y.
21. Tan WY, Young BE, Lye DC, Chew DE, Dalan RJSr. Statin use is associated with lower disease severity in COVID-19 infection. Sci Rep. 2020;10(1):1-7. doi: 10.1038/s41598-020-74492-0.
22. De Spiegeleer A, Bronselaer A, Teo JT, et al. The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents. J Am Med Dir Assoc.2020;21(7):909-914.e902. doi: 10.1016/j.jamda.2020.06.018.
23. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. 2020;383(19):1813-1826. doi: 10.1056/NEJMoa2007764.
24. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report [published online ahead of print, 2020 Jul 17]. N Engl J Med. 2020;NEJMoa2021436. doi:10.1056/NEJMoa2021436.
25. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatol. 2020;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9.
26. Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. The Lancet Rheumatol.2020;2(7):e393-e400. doi: 10.1016/S2665-9913(20)30164-8.
27. Ziaie, S., Koucheck, M., Miri, et al. Review of therapeutic agents for the treatment of COVID-19. J Cell Mol Anesth . 2020;5(1):32-36. doi: 10.22037/jcma.v5i1.29760.
Table 1. Patient Demographics and Related Clinical and Laboratory Findings